Advancing Formulation and Stability Optimization

The development of new protein therapeutics is a complex and costly process, often hindered by late-stage failures due to poor drug-like properties or instability of drug candidates. In silico modeling has emerged as a powerful tool to identify potential risks early, analyze structural properties, and inform formulation optimization strategies. The integration of computational approaches with experimental developability assessments enables data-driven decision-making, reducing development time, costs and material constraints. This webinar explores recent advances in in-silico tools and demonstrates how computational methods streamline drug development and enhance formulation success.

Dr. Tim Menzen, Chief Technology Officer and Dr. Andrea Arsiccio, Senior Scientist both of Coriolis Pharma, will lead this informative session exploring computational approaches in pharmaceutical development. They will cover in silico applications and their key areas of use including particle identification, lyophilization process development, and developability assessment, alongside the integration of in silico models with experimental approaches to optimise drug development.

Including case studies demonstrating in silico modeling’s role in developability assessment and early formulation development, highlighting how these approaches minimise risks, shorten development times, and enhance decision-making. Gain valuable insights on how computational modeling is revolutionising pharmaceutical development workflows and creating more efficient pathways from discovery to clinical application, benefiting scientists and researchers across the industry.

An interactive Q&A session with the speakers will conclude the webinar.